Evidence map›Paper›PMID 35191970›Full record

ArticleJAMA network open2022

Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer.

Erin L Van Blarigan, Fang-Shu Ou, Tiffany M Bainter, Charles S Fuchs, Donna Niedzwiecki, Sui Zhang, Leonard B Saltz, Robert J Mayer, Alexander Hantel, Al B Benson and 9 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 1 country.

Erin L Van BlariganDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco.
Fang-Shu OuAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota.
Tiffany M BainterAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota.
Charles S FuchsYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Donna NiedzwieckiDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
Sui ZhangJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Leonard B SaltzMemorial Sloan Kettering Cancer Center, New York, New York.
Robert J MayerDana-Farber Cancer Institute, Boston, Massachusetts.
Alexander HantelEdward Hematology Oncology Group, Naperville, Illinois.
Al B BensonRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
Daniel AtienzaVirginia Oncology Associates, Norfolk.
Michael MessinoSoutheast Clinical Oncology Research Consortium, Mission Hospitals, Inc, Asheville, North Carolina.
Hedy L KindlerUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois.
Alan P VenookHelen Diller Family Comprehensive Cancer Center, San Francisco, California.
Shuji OginoProgram in Molecular Pathology Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Hanna K SanoffUniversity of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill.
Edward L GiovannucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Kimmie NgDana-Farber Cancer Institute, Boston, Massachusetts.
Jeffrey A MeyerhardtDana-Farber Cancer Institute, Boston, Massachusetts.
Dana-Farber Cancer Institute · USMayo Clinic · USBrigham and Women's Hospital · USBroad Institute · USDuke University · USJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USNorthwestern University · USSoutheast Clinical Oncology Research Consortium · USUCSF Helen Diller Family Comprehensive Cancer Center · USUNC Lineberger Comprehensive Cancer CenterUniversity of California, San Francisco · USUniversity of Chicago · USVirginia Oncology Associates · USYale Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
Southeast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8M
SOUTHEAST CANCER CONTROL COSORTIUM, INCU10CA045808 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI ATKINS, JAMES NORMAN · 1987 to 2013
$26.6M
Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867 · NCI · DANA-FARBER CANCER INST · PI BURSTEIN, HAROLD JOHN, KIBEL, ADAM S · 2014 to 2018
$6.2M
Accelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0M
Yale Cancer Center NCTN LAPSUG1CA233337 · NCI · YALE UNIVERSITY · PI ANNE C CHIANG · 2019 to 2026
$6.0M
NCI NIH HHS K07 CA197077NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA118553NCI NIH HHS R35 CA197735NCI NIH HHS U10 CA032291NCI NIH HHS U10 CA041287NCI NIH HHS U10 CA045808NCI NIH HHS U10 CA077651NCI NIH HHS U10 CA138561NCI NIH HHS U10 CA180791NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180836NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189858NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233290NCI NIH HHS UG1 CA233327NCI NIH HHS UG1 CA233337NCI NIH HHS UG1 CA233373
6 · The paper itself

Abstract

Importance: The American Cancer Society and American Institute for Cancer Research recommend that cancer survivors limit intake of red and processed meats. This recommendation is based on consistent associations between red and processed meat intake and cancer risk, particularly risk of colorectal cancer, but fewer data are available on red and processed meat intake after cancer diagnosis. Objectives: To examine whether intake of unprocessed red meat or processed meat is associated with risk of cancer recurrence or mortality in patients with colon cancer. Design, Setting, and Participants: This prospective cohort study used data from participants with stage III colon cancer enrolled in the Cancer and Leukemia Group B (CALGB 89803/Alliance) trial between 1999 and 2001. The clinical database for this analysis was frozen on November 9, 2009; the current data analyses were finalized in December 2021. Exposures: Quartiles of unprocessed red meat and processed meat intake assessed using a validated food frequency questionnaire during and 6 months after chemotherapy. Main Outcomes and Measures: Hazard ratios (HRs) and 95% CIs for risk of cancer recurrence or death and all-cause mortality. Results: This study was conducted among 1011 patients with stage III colon cancer. The median (IQR) age at enrollment was 60 (51-69) years, 442 patients (44%) were women, and 899 patients (89%) were White. Over a median (IQR) follow-up period of 6.6 (1.9-7.5) years, we observed 305 deaths and 81 recurrences without death during follow-up (386 events combined). Intake of unprocessed red meat or processed meat after colon cancer diagnosis was not associated with risk of recurrence or mortality. The multivariable HRs comparing the highest vs lowest quartiles for cancer recurrence or death were 0.84 (95% CI, 0.58-1.23) for unprocessed red meat and 1.05 (95% CI, 0.75-1.47) for processed meat. For all-cause mortality, the corresponding HRs were 0.71 (95% CI, 0.47-1.07) for unprocessed red meat and 1.04 (95% CI, 0.72-1.51) for processed meat. Conclusions and Relevance: In this cohort study, postdiagnosis intake of unprocessed red meat or processed meat was not associated with risk of recurrence or death among patients with stage III colon cancer.

Indexed as

Colonic NeoplasmsAgedDietFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalProportional Hazards ModelsProspective StudiesRed Meat

Identifiers

PMID35191970
PMCPMC8864503
OpenAlexW4212812642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.